Summit Study - FAQs

FAQs

About the ASCEND Study:

View All FAQ Answers
This clinical research study is evaluating an investigational nasal powder to treat acute migraines in adults. You may be able to take part in this study if you:
  • Are 18 to 65 years of age
  • Have had migraines for at least 1 year
  • Have 2 to 8 migraine attacks each month
  • Have less than 15 total headache days each month

The study will involve 3 visits to the study center, which take place over the course of several months, and will enroll approximately 1,400 participants. 


The first visit (Visit 1) is for screening, and the study team will evaluate your eligibility to participate. If you proceed, you will receive training on the use of the investigational nasal device, use of the electronic diary, and will complete a series of health assessments and laboratory tests. Training and health assessments will also be part of Visit 2, and if you qualify, you will receive the investigational medicine to take home for use during your next migraine. Visit 3 is the final visit, and you will complete final study procedures and return study materials such as the used investigational device and e-diary device. 

If eligible, participation can last several months, which includes 3 visits to the study center.

The study medication is an investigational nasal powder, administered via a pre-filled, single-use electronic device. 

Do not discontinue any medication unless you are advised to do so by the study center staff or your primary care physician.

There is no cost to you for participating in the study. 

Clinical research studies are designed in specific ways, and one or more of the answers that you provided were outside of the guidelines for this study. This does not mean you will not qualify for different research studies.

This clinical research study is evaluating an investigational nasal powder to treat acute migraines in adults. You may be able to take part in this study if you:
  • Are 18 to 65 years of age
  • Have had migraines for at least 1 year
  • Have 2 to 8 migraine attacks each month
  • Have less than 15 total headache days each month

The study will involve 3 visits to the study center, which take place over the course of several months, and will enroll approximately 1,400 participants. 


The first visit (Visit 1) is for screening, and the study team will evaluate your eligibility to participate. If you proceed, you will receive training on the use of the investigational nasal device, use of the electronic diary, and will complete a series of health assessments and laboratory tests. Training and health assessments will also be part of Visit 2, and if you qualify, you will receive the investigational medicine to take home for use during your next migraine. Visit 3 is the final visit, and you will complete final study procedures and return study materials such as the used investigational device and e-diary device. 

If eligible, participation can last several months, which includes 3 visits to the study center.

The study medication is an investigational nasal powder, administered via a pre-filled, single-use electronic device. 

Do not discontinue any medication unless you are advised to do so by the study center staff or your primary care physician.

There is no cost to you for participating in the study. 

Clinical research studies are designed in specific ways, and one or more of the answers that you provided were outside of the guidelines for this study. This does not mean you will not qualify for different research studies.

The SUMMIT Study is evaluating a new investigational medicine for the acute treatment of migraines.